Juncell Therapeutics Announces Data on Feeder-free IL-2-Independent TIL Manufacturing Process at ASGCT Annual Meeting 2025

Juncell Therapeutics Announces Data on Feeder-free IL-2-Independent TIL Manufacturing Process at ASGCT Annual Meeting 2025 News provided by Shanghai Juncell Therapeutics Co., Ltd. Apr 28, 2025, 20:08 ET Share this article Share to X Share this article Share to X SHANGHAI , April 28, 2025 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech specializing in developing innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies for cancer, today announced it will present preclinical data on a feeder-free manufacturing process for IL-2-independent TIL expansion at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place May 13–15, 2025, in New Orleans, LA . The study highlights Juncell Therapeutics' breakthroughs in TIL process development, demonstrating that its proprietary feeder-free system can generate robust, functional TILs from both "hot" and "cold" tumor tissues without relying on high-concentration interleukin-2 (IL-2). These TILs exhibited significant anti-tumor activity in syngeneic patient-derived organoid (PDO) and patient-derived xenograft (PDX) models. By eliminating IL-2 dependence and removing the need for feeder cells, the technology paves the way for safer TIL treatment regimens and reduces manufacturing costs. Presentation Details: Title: Development of A Feeder-Free Process for IL-2-Independent TIL Expansion Poster Number: AMA362 Session: Thursday Poster Reception Date and Time: May 15, 2025 , 5:30 PM–7:00 PM Location: Poster Hall Hall I2 About Juncell Therapeutics Juncell Therapeutics is a biotech dedicated to developing high-quality, accessible IL-2 independent TIL therapies for the treatment of solid tumors. Juncell Therapeutics has established its proprietary DeepTIL® cell expansion and NovaGMP® gene modification technology platforms, which are designed to address the key challenges of conventional TIL therapies, making TILs "robust, competent, affordable, and accessible." Two clinical-stage TIL therapies have demonstrated promising safety and efficacy in the treatment of ten types of heavily pretreated advanced solid tumors, including lung cancer, triple-negative breast cancer, pancreatic cancer, high-grade glioma, ovarian cancer, endometrial cancer, cervical cancer, head and neck cancer, bile duct cancer and melanoma. For more information, please visit: https://www.juncell.com/en https://www.linkedin.com/company/juncell-therapeutics Juncell Contact: [email protected] SOURCE Shanghai Juncell Therapeutics Co., Ltd. 21 % more press release views with Request a Demo × Modal title